Caplin Point Laboratories Past Earnings Performance
Past criteria checks 6/6
Caplin Point Laboratories has been growing earnings at an average annual rate of 18.7%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 18.3% per year. Caplin Point Laboratories's return on equity is 21%, and it has net margins of 26.8%.
Key information
18.7%
Earnings growth rate
18.7%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 18.3% |
Return on equity | 21.0% |
Net Margin | 26.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Caplin Point Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 16,318 | 4,376 | 1,430 | 632 |
30 Sep 23 | 15,683 | 4,179 | 1,408 | 632 |
30 Jun 23 | 15,157 | 3,947 | 1,396 | 0 |
31 Mar 23 | 14,683 | 3,763 | 1,371 | 632 |
31 Dec 22 | 14,182 | 3,532 | 1,314 | 593 |
30 Sep 22 | 13,724 | 3,307 | 1,262 | 593 |
30 Jun 22 | 13,153 | 3,140 | 1,210 | 0 |
31 Mar 22 | 12,710 | 2,998 | 1,154 | 593 |
31 Dec 21 | 12,099 | 2,872 | 1,110 | 537 |
30 Sep 21 | 11,581 | 2,767 | 1,071 | 537 |
30 Jun 21 | 11,217 | 2,586 | 1,034 | 0 |
31 Mar 21 | 10,624 | 2,423 | 1,026 | 537 |
31 Dec 20 | 9,986 | 2,248 | 952 | 530 |
30 Sep 20 | 9,524 | 2,189 | 874 | 530 |
30 Jun 20 | 9,107 | 2,193 | 780 | 0 |
31 Mar 20 | 8,640 | 2,150 | 678 | 530 |
31 Dec 19 | 8,356 | 2,159 | 617 | 282 |
30 Sep 19 | 7,664 | 2,032 | 557 | 282 |
30 Jun 19 | 6,948 | 1,894 | 512 | 0 |
31 Mar 19 | 6,490 | 1,766 | 471 | 282 |
31 Dec 18 | 6,048 | 1,621 | 449 | 237 |
30 Sep 18 | 5,874 | 1,538 | 431 | 237 |
30 Jun 18 | 5,628 | 1,459 | 417 | 0 |
31 Mar 18 | 5,399 | 1,448 | 391 | 237 |
31 Dec 17 | 5,145 | 1,430 | 367 | 141 |
30 Sep 17 | 4,757 | 1,297 | 352 | 141 |
30 Jun 17 | 4,401 | 1,165 | 322 | 0 |
31 Mar 17 | 4,016 | 956 | 321 | 141 |
31 Dec 16 | 3,655 | 783 | 300 | 54 |
30 Sep 16 | 3,420 | 703 | 274 | 54 |
30 Jun 16 | 3,238 | 619 | 258 | 54 |
31 Mar 16 | 3,088 | 584 | 240 | 54 |
31 Dec 15 | 2,906 | 535 | 298 | 67 |
30 Sep 15 | 2,722 | 465 | 283 | 60 |
30 Jun 15 | 2,518 | 410 | 203 | 59 |
31 Mar 15 | 2,296 | 353 | 233 | 53 |
31 Dec 14 | 2,074 | 318 | 220 | 42 |
30 Sep 14 | 1,893 | 305 | 204 | 33 |
30 Jun 14 | 1,731 | 258 | 190 | 21 |
31 Mar 14 | 1,643 | 204 | 166 | 4 |
31 Dec 13 | 1,517 | 167 | 149 | 0 |
30 Sep 13 | 1,408 | 125 | 137 | 0 |
30 Jun 13 | 1,270 | 140 | 125 | 7 |
Quality Earnings: 524742 has high quality earnings.
Growing Profit Margin: 524742's current net profit margins (26.8%) are higher than last year (24.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524742's earnings have grown by 18.7% per year over the past 5 years.
Accelerating Growth: 524742's earnings growth over the past year (23.9%) exceeds its 5-year average (18.7% per year).
Earnings vs Industry: 524742 earnings growth over the past year (23.9%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 524742's Return on Equity (21%) is considered high.